Drug Profile
Research programme: cancer therapeutics - sigma-tau
Alternative Names: DN-30; MvDN 30Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator sigma-tau SpA
- Class Antibodies
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Italy (Parenteral)
- 29 Feb 2016 DN 30 is available for licensing as of 29 Feb 2016. http://www.sigma-tau.it
- 20 Aug 2010 Preclinical development is ongoing in Italy